Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04032418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results posted: Sep 21, 2026
    • Study completion pushed from Jun 14, 2026 to Sep 14, 2026
    • Eligibility criteria shortened, about 27 words
    • Secondary endpoints: details revised at 2 of 2 entries
  2. Study completion date: Jun 14, 2026 to Sep 14, 2026
    • Secondary endpoints revised (2)
    • Primary endpoint revised
    v19
  3. Study completion date: Mar 14, 2026 to Jun 14, 2026v18
  4. Primary completion date: Mar 14, 2024 to Mar 14, 2025
    • Study completion date: Mar 14, 2025 to Mar 14, 2026
    v17
  5. Primary completion date: Jan 5, 2024 to Mar 14, 2024
    • Study completion date: Jan 5, 2025 to Mar 14, 2025
    v16
Show 14 earlier versionsHide 14 earlier versions
  1. Primary completion date: Jan 1, 2024 to Jan 5, 2024v15
  2. Primary completion date changed from estimate of Jan 5, 2025 to Jan 1, 2024v14
  3. Primary completion date: Jan 5, 2024 to Jan 5, 2025v13
  4. Primary completion date: Nov 3, 2023 to Jan 5, 2024
    • Study completion date: Nov 3, 2023 to Jan 5, 2025
    v12
  5. Primary and study completion dates: Sep 3, 2023 to Nov 3, 2023v11
  6. Enrollment target: estimated 152 to confirmed 9
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v10
  7. Primary completion date: Sep 3, 2022 to Sep 3, 2023
    • Start date: Feb 13, 2020 to Aug 13, 2020
    v9
  8. Collaborators shortened, about 4 wordsv8
  9. Eligibility criteria expanded, about 53 words
    • Study description expanded, about 2 words
    v7
  10. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 30, 2020 to Feb 13, 2020
    • Site details revised
    v6
  11. Start date: Dec 30, 2019 to Mar 30, 2020v5
  12. Start date: Nov 3, 2019 to Dec 30, 2019v4
  13. Start date: Sep 3, 2019 to Nov 3, 2019v3
  14. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well pembrolizumab given every 12 weeks works compared to every 3 weeks in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab every 12 weeks may provide similar disease control with fewer treatments for patients with non-small cell lung cancer when compared to every 3 weeks. Demonstrating that 12 week dosing is as effective as 3 week dosing may also have a significant impact when considering the cost required for these medications.
Trial Details
NCT Number NCT04032418
Lead Sponsor Roswell Park Cancer Institute
Conditions
(from sponsor)		 Lung Non-Small Cell Carcinoma
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov